Crohn's Disease Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, NDA Approvals, Medication, Pipeline, Epidemiology and Companies by DelveInsight
(Albany, USA) DelveInsight's ' Crohn's Disease Market Insights, Epidemiology, and Market Forecast-2034 ' report delivers an in-depth understanding of Crohn's Disease, historical and forecasted epidemiology as well as the Crohn's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Crohn's Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Crohn's Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Crohn's Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Crohn's Disease market.
Some facts of the Crohn's Disease Market Report are:
The Crohn's disease market size in the 7MM was observed to be USD ~9,000 million in 2023, which is expected to increase by 2034.
Key Crohn's Disease Therapies expected to launch in the market are ENTYVIO (Vedolizumab), STELARA (Ustekinumab), VELSIPITY (etrasimod), Zeposia (Ozanimod; RPC1063), LY-3074828 (mirikizumab), RHB-104, and others.
In Feb 2025, Janssen Research & Development, LLC announced results of a Phase 4, Single Arm, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab (STELARA), an Anti-Interleukin-12/23 Monoclonal Antibody, in Chinese Participants With Moderately to Severely Active Crohn's Disease
In Feb 2025, Janssen Research & Development, LLC announced results of a Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
In Jan 2025, Eli Lilly and Company announced results of a Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
On October 14, 2024, Eli Lilly and Company reported that more patients with moderately to severely active Crohn's disease treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab, regardless of prior biologic experience. The VIVID-1 study is the first Phase 3 trial to report histologic outcomes using a systematic assessment of bowel segments, following ECCO guidelines. These results are being presented at UEG Week in Vienna from October 12-15.
On October 14, 2024, Johnson & Johnson reported positive results for TREMFYA (guselkumab) in Crohn's disease and ulcerative colitis at the United European Gastroenterology (UEG) Week 2024. The data showed high rates of endoscopic remission in biologic-naïve and biologic-refractory patients, including those unresponsive to JAK inhibitors. These findings from the Phase III GALAXI 2 & 3 studies and the QUASAR maintenance study suggest TREMFYA could be a valuable treatment option for patients who have not responded to other biologics.
Leading Crohn's Disease companies working in the market are Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast, and others.
On October 14, 2024, Dong-A-ST announced that its Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar to Stelara, received FDA approval for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Stelara, a blockbuster drug developed by Janssen Biotech, generated $10.86 billion in sales globally in 2023, and Imuldosa's approval as a biosimilar offers a more cost-effective alternative for patients requiring long-term therapy for autoimmune conditions.
Crohn's Disease Overview
Crohn's Disease is a chronic inflammatory bowel disease (IBD) that causes inflammation in the gastrointestinal (GI) tract, most commonly affecting the small intestine and colon. This progressive condition leads to symptoms such as abdominal pain, persistent diarrhea, fatigue, weight loss, and malnutrition. The exact cause of Crohn's Disease remains unclear, but it is believed to result from a combination of genetic, environmental, and immune system factors.
The disease presents in different forms, including ileocolitis (affecting the ileum and colon), ileitis (limited to the ileum), gastroduodenal Crohn's Disease (impacting the stomach and duodenum), jejunoileitis (small intestine inflammation), and Crohn's colitis (restricted to the colon). Complications such as strictures, fistulas, abscesses, and bowel obstructions can occur, requiring advanced medical intervention.
Treatment options for Crohn's Disease aim to manage inflammation, alleviate symptoms, and prevent flare-ups. Common therapies include aminosalicylates, corticosteroids, immunomodulators, biologics (such as TNF inhibitors and integrin inhibitors), and JAK inhibitors. In severe cases, surgery may be necessary to remove damaged portions of the intestine. Ongoing research focuses on new targeted therapies, gut microbiome modulation, and personalized treatment approaches to improve long-term outcomes for Crohn's Disease patients.
Learn more about Crohn's Disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Crohn's Disease Prevalence
Crohn's Disease Market
The Crohn's disease market is a rapidly evolving segment in the healthcare industry, driven by increasing prevalence, advances in treatment options, and a growing focus on precision medicine. Crohn's disease, a chronic inflammatory bowel disease (IBD), affects the gastrointestinal tract, causing symptoms like abdominal pain, diarrhea, weight loss, and fatigue. Its progressive nature often leads to complications, necessitating long-term management.
The market is dominated by biologics, including tumor necrosis factor (TNF) inhibitors such as infliximab and adalimumab, which remain the cornerstone of treatment. However, emerging therapies like interleukin inhibitors (ustekinumab) and Janus kinase (JAK) inhibitors (upadacitinib) are gaining traction due to improved efficacy and targeted mechanisms of action. Small molecule drugs and biosimilars are further expanding therapeutic options, offering cost-effective solutions.
Key players in the market include AbbVie, Janssen Pharmaceuticals, Takeda, UCB, and Gilead Sciences, among others. The pipeline for Crohn's disease treatments is robust, with several novel agents focusing on enhancing efficacy, safety, and patient convenience.
Regional markets such as North America and Europe lead in revenue due to advanced healthcare infrastructure and higher awareness. The market's future is shaped by increasing patient populations, innovative treatment approaches, and ongoing research into the disease's underlying mechanisms.
Crohn's Disease Epidemiology
The Crohn's Disease epidemiology section provides insights into the historical and current Crohn's Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Crohn's Disease market report also provides the diagnosed patient pool, trends, and assumptions.
Crohn's Disease Drugs Uptake
This section focuses on the uptake rate of the potential Crohn's Disease drugs recently launched in the Crohn's Disease market or expected to be launched in 2020-2034. The analysis covers the Crohn's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Crohn's Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Crohn's Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Crohn's Disease Pipeline Development Activities
The Crohn's Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Crohn's Disease key players involved in developing targeted therapeutics.
Download the report to understand which factors are driving Crohn's Disease market trends @ Crohn's Disease Market Insights
Crohn's Disease Therapeutics Assessment
Major key companies are working proactively in the Crohn's Disease Therapeutics market to develop novel therapies which will drive the Crohn's Disease treatment markets in the upcoming years are Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast, and others.
Crohn's Disease Report Key Insights
1. Crohn's Disease Patient Population
2. Crohn's Disease Market Size and Trends
3. Key Cross Competition in the Crohn's Disease Market
4. Crohn's Disease Market Dynamics (Key Drivers and Barriers)
5. Crohn's Disease Market Opportunities
6. Crohn's Disease Therapeutic Approaches
7. Crohn's Disease Pipeline Analysis
8. Crohn's Disease Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Crohn's Disease Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Crohn's Disease Competitive Intelligence Analysis
4. Crohn's Disease Market Overview at a Glance
5. Crohn's Disease Disease Background and Overview
6. Crohn's Disease Patient Journey
7. Crohn's Disease Epidemiology and Patient Population
8. Crohn's Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Crohn's Disease Unmet Needs
10. Key Endpoints of Crohn's Disease Treatment
11. Crohn's Disease Marketed Products
12. Crohn's Disease Emerging Therapies
13. Crohn's Disease Seven Major Market Analysis
14. Attribute Analysis
15. Crohn's Disease Market Outlook (7 major markets)
16. Crohn's Disease Access and Reimbursement Overview
17. KOL Views on the Crohn's Disease Market
18. Crohn's Disease Market Drivers
19. Crohn's Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
· In Feb 2025, Janssen Research & Development, LLC announced results of a Phase 4, Single Arm, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab (STELARA), an Anti-Interleukin-12/23 Monoclonal Antibody, in Chinese Participants With Moderately to Severely Active Crohn's Disease
· In Feb 2025, Janssen Research & Development, LLC announced results of a Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
· In Jan 2025, Eli Lilly and Company announced results of a Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
30-07-2025
- Globe and Mail
Sleep Apnea Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Sleep Apnea Pipeline Insight, 2025' report provides comprehensive insights about 10+ companies and 14+ pipeline drugs in Sleep Apnea pipeline landscape. It covers the Sleep Apnea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sleep Apnea pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Sleep Apnea Treatment Landscape. Click here to read more @ Sleep Apnea Pipeline Outlook Key Takeaways from the Sleep Apnea Pipeline Report In July 2025, Mineralys Therapeutics Inc. announced a study is a randomized, double-blind (DB), placebo controlled, crossover study. A 4-week screening period is followed by two DB 4-week treatment periods separated by a 2-week washout period. Participants must be 18 to 75 years old with moderate to severe OSA, hypertension and meet all applicable eligibility criteria. Participants who are medically prescribed and deemed compliant with positive airway pressure (PAP) therapy for greater than or equal to (>=) 4 hours per night (Continuous PAP [CPAP], or automatic PAP [autoPAP]) and for at least 3 months prior to the study enrollment are eligible for the study. In July 2025, Eli Lilly and Company announced a study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study. DelveInsight's Sleep Apnea pipeline report depicts a robust space with 10+ active players working to develop 14+ pipeline therapies for Sleep Apnea treatment. The leading Sleep Apnea Companies such as Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Phamaceuticals, Neurim Pharmaceuticals and others. Promising Sleep Apnea Pipeline Therapies such as Sivopixant, Acetazolamide, SAS0421a, VI-0521, Zonisamide, Sulthiame, AD128, BAY2586116 and others. Stay informed about the cutting-edge advancements in Sleep Apnea Treatments. Download for updates and be a part of the revolution in dermatology care @ Sleep Apnea Clinical Trials Assessment Sleep Apnea Emerging Drugs Profile AD109: Apnimed AD109 is an investigational oral therapy, a pill designed to target the underlying neuromuscular dysfunction in people living with mild, moderate, and severe obstructive sleep apnea (OSA). This novel treatment targets the hypoglossal motor nucleus (HMN) to increase signals in the upper airway dilator muscles during sleep to limit or prevent airway collapse. It is a potential first-in-class, novel, investigational combination dosed once daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity. AD109 combines company's novel selective antimuscarinic (aroxybutynin) with a selective norepinephrine reuptake inhibitor (atomoxetine). AD109 targets key neurological pathways in OSA that activate upper airway dilator muscles to maintain an open airway during sleep. AD109 has the potential to become a safe, effective, and convenient treatment for OSA, addressing some of the key limitations of current standard of care treatments that can be poorly tolerated (e.g., CPAP and oral devices) and/or invasive (e.g., surgery or implanted devices). Currently, the drug is in the Phase III stage of its development for the treatment of Obstructive Sleep Apnea. Dronabinol: RespireRx Phamaceuticals Dronabinol is a synthetic form of tetrahydrocannabinol (THC), the active compound in cannabis, primarily used to treat nausea, vomiting, and appetite loss. Research has shown potential for dronabinol in treating sleep apnea by stimulating the body's endocannabinoid receptors, which may help reduce apnea episodes and stabilize breathing during sleep. While not yet FDA-approved for sleep apnea, clinical studies suggest it could be beneficial in managing obstructive sleep apnea (OSA) symptoms. Currently, the drug is in the Phase II stage of its development for the treatment of Sleep Apnea. Gal 475: Neurim Pharmaceuticals GAL-475 is a novel therapeutic agent for the treatment of sleep apnea syndromes. In a series of in vitro and in vivo studies in various animal models it demonstrated improvements in sleep apnea indices with reductions in both the frequency and severity of events, without stimulating minute ventilation or disturbing sleep. Preclinical pharmacology studies with GAL-475 suggest that the compound acts predominantly as a peripheral chemoreception modulator, and indicate that the compound is effective in increasing respiratory drive to the upper airways and ameliorating obstructive apneas and their attendant sequelae in rodent models of obstructive apnea at relatively low plasma levels. The primary site of action for GAL-475 appears to be at the level of the carotid body, a peripheral polymodal chemosensory organ, located at the carotid bifurcation, responsible for sensing changes in partial pressures of O2, CO2 or pH, and activating the brainstem respiratory center to produce hyperventilation. Currently, the drug is in the Phase I stage of its development for the treatment of Sleep Apnea. The Sleep Apnea pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Sleep Apnea with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sleep Apnea Treatment. Sleep Apnea Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Sleep Apnea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sleep Apnea market. Get a detailed analysis of the latest innovations in the Sleep Apnea pipeline. Explore DelveInsight's expert-driven report today! @ Sleep Apnea Unmet Needs Sleep Apnea Companies Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Phamaceuticals, Neurim Pharmaceuticals and others. Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Sleep Apnea Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Sleep Apnea Treatment by visiting our website. Stay informed about how we're transforming the future of Dermatology @ Sleep Apnea Market Drivers and Barriers, and Future Perspectives Scope of the Sleep Apnea Pipeline Report Coverage- Global Sleep Apnea Companies- Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Phamaceuticals, Neurim Pharmaceuticals and others. Sleep Apnea Pipeline Therapies- Sivopixant, Acetazolamide, SAS0421a, VI-0521, Zonisamide, Sulthiame, AD128, BAY2586116 and others. Sleep Apnea Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Sleep Apnea Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Sleep Apnea Pipeline on our website @ Sleep Apnea Emerging Drugs and Companies Table of Contents Introduction Executive Summary Sleep Apnea: Overview Pipeline Therapeutics Therapeutic Assessment Sleep Apnea– DelveInsight's Analytical Perspective Late Stage Products (Phase III) AD109: Apnimed Drug profiles in the detailed report….. Mid Stage Products (Phase II) Dronabinol: RespireRx Phamaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) Gal 475: Neurim Pharmaceuticals Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Sleep Apnea Key Companies Sleep Apnea Key Products Sleep Apnea- Unmet Needs Sleep Apnea- Market Drivers and Barriers Sleep Apnea- Future Perspectives and Conclusion Sleep Apnea Analyst Views Sleep Apnea Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
CTV News
19-07-2025
- CTV News
Workshop focuses on artistic expressions in research dissemination
Oghenevwede Oturuhoyi, a summer intern with the Black Equity in Alberta Rainforest project, is seen at a workshop on July 19, 2025. (CTV News Edmonton/Galen McDougall) African, Caribbean and Black (ACB) artists gathered at the University of Alberta Saturday morning for a professional development seminar hosted by the Ribbon Rouge Foundation and the Black Equity in Alberta Rainforest (BEAR) research project. Several speakers presented at the workshop, sharing their works and how the research influenced what they do. Oghenevwede Oturuhoyi, a summer intern with BEAR, said the workshop is important to the research project which looks at the root causes of ACB related health inequity. 'We're talking about knowledge translation – how do we translate our knowledge or data to reach the grassroots, to get to ACB communities, people who cannot access written information?' Oturuhoyi told CTV News Edmonton. 'We're really interested in how this knowledge can be transmitted and assessed.' Oturuhoyi said the workshop will give BEAR the opportunity to learn how to break down knowledge and disseminate the information through various artistic mediums. The first segment of the workshop involved presentations about BEAR's objectives and how they fit into those of Ribbon Rouge. The Ribbon Rouge Foundation is a grassroots organization focused on health equity and facilitates social justice through the arts. The second phase of the workshop took a more interactive approach with informal discussions about the subject matter. 'Today is all about learning, equipping and developing ourselves,' said Oturuhoyi. BEAR and the Ribbon Rouge Foundation are planning to hold a symposium in August, where they are looking to commission artists to translate some of the BEAR's findings into artistic expressions.
Cision Canada
15-07-2025
- Cision Canada
Health Canada Approves Lilly's Omvoh® (mirikizumab) for Crohn's Disease; New Citrate-Free Formulation Français
Omvoh ® is now indicated for both major forms of Inflammatory Bowel Disease (IBD) – ulcerative colitis (UC) and Crohn's disease (CD) In VIVID-1, Omvoh ® showed statistically significant and clinically meaningful efficacy across multiple endpoints compared with placebo in patients with moderately to severely active CD, meeting the coprimary composite endpoints and all major secondary endpoints. 3 Health Canada has also approved a new citrate-free formulation of Omvoh ® for subcutaneous injection, which contains the same active ingredients as the original Omvoh ®. TORONTO, July 15, 2025 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh ® (mirikizumab) for CD, which will soon be available to patients in Canada. Omvoh ® is an interleukin-23p19 antagonist for the treatment of adult patients with moderately to severely active CD who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment. 1 Health Canada has also approved a new citrate-free formulation of Omvoh ® for subcutaneous injection, for the existing UC indication, as well as the new CD indication. "We are pleased to see that Omvoh ® will now be able to provide people living with moderately to severely active CD an effective and safe option for treatment," said Mathilde Merlet, President and General Manager of Lilly Canada. "With this additional indication, we are reinforcing our commitment to helping more of the IBD community. Additionally, we are proud to be able to introduce a new citrate-free formulation, which we hope will improve the patient experience, while offering the same quality, efficacy, and safety that patients are accustomed to." The authorization of Omvoh ® for CD was based on results from the VIVID-1 clinical study, which included over 1,000 adults. In VIVID-1, mirikizumab showed statistically significant and clinically meaningful efficacy across multiple endpoints compared with placebo in patients with moderately-to-severely active CD, meeting the coprimary composite endpoints and all major secondary endpoints. The coprimary composite endpoints included patient-reported outcome (PRO) clinical response at week 12 and endoscopic response at week 52 (endoscopic response-composite), and PRO clinical response at week 12 and Crohn's Disease Activity Index (CDAI) clinical remission at week 52 (CDAI clinical remission-composite). Endoscopic response-composite was reached in 220 (38%) of 579 patients on mirikizumab versus 18 (9%) of 199 patients on placebo; CDAI clinical remission-composite was reached in 263 (45%) of 579 patients on mirikizumab versus 39 (20%) of 199 patients on placebo. Statistical significance was also observed in subgroups with and without failure to biological therapies for coprimary endpoints and most major secondary endpoints. 3 The Community Reacts: Sylvain Chiasson, Interim President & CEO of Crohn's and Colitis Canada: "Crohn's and Colitis Canada always welcomes new treatments for people with CD in Canada. CD is a chronic autoimmune disease where the immune system attacks the gastrointestinal system. CD is a complex disease that is debilitating, leads to hospitalizations and surgeries, and has a tremendous impact on the quality of life for the approximately 162,000 Canadians living with this disease. Because of the disease's complexity, not all people with CD respond in the same way to the available treatments. So, it is welcome news for Crohn's and Colitis Canada when there is a new therapy available for people with CD." Gail Attara, Chief Executive Officer of the Gastrointestinal Society ( "We are so pleased to learn that Health Canada has approved a CD indication for Omvoh (mirikizumab). Compared to other inflammatory conditions, CD has very few medications, so the introduction of Omvoh's expanded use as a new option is excellent news for the IBD community." Dr. John Marshall, Professor of Medicine, and Director of the Division of Gastroenterology at McMaster University: "It is exciting to see a new and highly effective therapy being made available for people living with CD. Clinical trials have shown mirikizumab to be both safe and effective, and this will be an appealing treatment option for patients who are new to biologic therapies, or those who have not responded adequately to previous advanced therapies." About the VIVID-1 Clinical Trial Program VIVID-1 was a Phase 3, randomized, double-blind, treat-through study that evaluated the safety and efficacy of mirikizumab compared with placebo and an active control (ustekinumab) in adults with moderately to severely active CD. Patients randomized to mirikizumab were administered 900 mg of mirikizumab intravenously every four weeks from Weeks 0-8, then 300 mg subcutaneously every four weeks from Weeks 12-52. In this study, 49% of patients treated with mirikizumab or placebo had experienced a prior biologic failure. 2 The overall safety profile of mirikizumab in patients with moderately to severely active CD was consistent with the known safety profile in patients with UC. The frequency of serious adverse events was greater in placebo than mirikizumab. The most common adverse events were upper respiratory tract infections, injection site reactions, headache, and rash. 1 About Omvoh ® Omvoh ® (mirikizumab) is an interleukin-23p19 (IL-23) antagonist indicated for the treatment of moderately to severely active UC and CD in adults. Omvoh ® selectively targets the p19 subunit of IL-23 and inhibits the IL-23 pathway. Inflammation due to overactivation of the IL-23 pathway plays a critical role in the pathogenesis of CD, a chronic, IBD associated with progressive bowel damage, disability and decreased health-related quality of life. For more information about Omvoh ®, please refer to the product monograph on About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. Lilly has been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Lilly's Canadian Affiliate, Eli Lilly Canada Inc. was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world's first commercially available insulin. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more about Lilly Canada, visit or follow us on LinkedIn. Omvoh ® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
